$AGX

Griffin William F Jr sold $32.2M of AGX (indirect holdings)

Griffin William F Jr sold 50,000 indirectly-held shares of ARGAN INC (AGX) at $643.46 ($32.17M total) on 2026-06-12.

Original reporting
SEC EDGAR · Griffin William F Jr
Published Jun 16, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AGX
Neutral
medium confidence
Mentioned
$AGX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AGXNeutralLow
01

Why it matters

The newest concrete fact is the director’s open-market sale of 50,000 shares at $643.46/share, totaling ~$32.17M, with holdings after the sale reported as 90,976 shares.

02

Market read

Traders may monitor for follow-on insider activity or any concurrent fundamental news, but this filing alone is unlikely to drive a durable repricing.

03

What to watch

The sale is indirect and the filing does not explain motives; traders should avoid extrapolating without corroborating fundamentals or additional insider activity.

Relevance 7/10Novelty 6/10Timing: Filed 2026-06-16; transaction dated 2026-06-12

Background

The article is an SEC Form 4 insider transaction disclosure for ARGAN Inc (AGX).

Company-level read

Ticker impact

$AGXNeutralMedium confidence
Context

SEC Form 4 shows director Griffin William F Jr sold 50,000 AGX shares for about $32.17M via an open-market sale.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and should fade unless followed by additional disclosures.

Evidence & confidence

The filing is a primary-source insider transaction, but it provides no new company fundamentals (no guidance, contract, or regulatory action).

Market effects

No sector-level read-across; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

A director sale can be routine liquidity/portfolio rebalancing and may not signal reduced confidence, especially with no 10b5-1 plan cited.

Key entities

  • ARGAN INC

    Subject of the SEC Form 4 insider transaction; director sold shares via open-market sale.

  • Griffin William F Jr

    Director who reported the sale of AGX shares; transaction dated 2026-06-12, filed 2026-06-16.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AGXMedAI 8/10

Argan’s (AGX) Power Boom Comes With A Margin Catch

Argan (AGX) reported record Q2 revenue of $384.0M (+61.5% YoY) and net income of $53.3M, driven by its Power segment. Gross margin slipped to 19.3%, and backlog decreased to $2.5B. The company is debt-free with $1.03B in cash, returning $51.7M to shareholders. Management expects new projects but faces regulatory challenges and margin compression.

$AGXHigh

Why Argan Stock Swooned by Almost 8% Today

Argan (AGX) stock fell 8% after Piper Sandler analyst Dimple Gosai initiated coverage with an underweight rating and a $273 price target, citing capacity limits and a potential peak in project awards.

$AGXMed

Argan (AGX) Q2 2027 Earnings Call Transcript

Argan (AGX) reported Q2 2027 revenue of $384.0M, up 61.5%, with net income of $53.3M ($3.76 per diluted share). Power segment revenue grew 53% YoY to $301M, while Industrial segment revenue rose 111% to $76M. Consolidated backlog decreased to $2.5B. The company plans to complete a new fabrication facility in North Carolina by Q3 2027.

$AGXMedAI 8/10

Is Argan Worth Buying as Growth Surges but Valuation Stays Elevated?

Argan, Inc. (AGX) reported 56.5% revenue growth to $674.9M and adjusted EBITDA growth to $126.5M in H1 2027. The company expects 45.4% sales and 38% earnings growth for fiscal 2027, with a $2.5B backlog. However, margins have declined, and valuation remains high. Management highlights multi-year visibility but warns of execution risks.